Cheng, Mingshan

Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions

Floc'h, N., Martin, M. J., Riess, J. W., Orme, J. P., Staniszewska, A. D., Ménard, L., Cuomo, M. E., O'Neill, D. J., Ward, R. A., Finlay, M. R. V., et al. (2018) · Molecular Cancer Therapeutics

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 115

Antitumor activity of osimertinib in NSCLC harboring EGFR exon 20 insertions

Riess, J., Floch, N., Martin, M., Orme, J., Staniszewska, A., Menard, L., Cuomo, M. E., O'Neill, D., Ward, R., Finlay, R., et al. (2017) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 8